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BACKGROUND: Endometriosis is estimated to affect 6-10% of women of reproductive age 33 
and it is associated with chronic pelvic pain, dysmenorrhea and subfertility. It is currently 34 
managed surgically or medically but symptoms recur in up to 75% of cases and available 35 
medical treatments have undesirable side effects. Endometriosis is defined as the presence of 36 
endometrial tissue outside the uterus with lesions typically found on the peritoneum. The 37 
aetiology of endometriosis is uncertain but there is increasing evidence that transforming 38 
growth factor (TGF)-β plays a major role.  39 
OBJECTIVE AND RATIONALE: A descriptive review was undertaken of the published 40 
literature on the expression pattern of TGF-β ligands and signalling molecules in women with 41 
and without endometriosis, and on the potential roles of TGF-β signalling in the development 42 
and progression of peritoneal endometriosis. The current understanding of the TGF-beta 43 
signaling pathway is summarized. 44 
SEARCH METHODS: We searched the Pubmed database using the terms ‘transforming 45 
growth factor beta’ and ‘endometriosis’ for studies published between 1995 and 2016. The 46 
initial search identified 99 studies and these were used as the basic material for this review. 47 
We also extended our remit for important older publications. In addition, we searched the 48 
reference lists of studies used in this review for additional studies we judged as relevant. 49 
Studies which were included in the review focused on peritoneal endometriosis only as 50 
increasing evidence suggests that ovarian and deep endometriosis may have a differing 51 
pathophysiology. Thus, a final 95 studies were included in the review.  52 
OUTCOMES: TGF-β1 is reported to be increased in the peritoneal fluid, serum, ectopic 53 
endometrium and peritoneum of women with endometriosis compared to women without 54 
endometriosis,  and TGF-β1-null mice have reduced endometriosis lesion growth when 55 
compared to their wild-type controls. Studies in mice and women have indicated that 56 
increasing levels of TGF-β ligands are associated with decreased immune cell activity within 57 
the peritoneum, together with an increase in ectopic endometrial cell survival, attachment, 58 































































invasion and proliferation, during endometriosis lesion development. TGF-β1 has been 59 
associated with changes in ectopic endometrial and peritoneal cell metabolism and the 60 
initiation of neoangiogenesis, further fuelling endometriosis lesion development.  61 
WIDER IMPLICATIONS: Together these studies suggest that TGF-β1 plays a major role 62 
in the development of peritoneal endometriosis lesions and that targeting this pathway may be 63 
of therapeutic potential. 64 
 65 
Keywords 66 
endometriosis, endometrium, peritoneum, smad, immune cells, angiogenesis  67 































































INTRODUCTION  68 
Endometriosis is estimated to affect 6-10% of women of reproductive age and is associated 69 
with chronic pelvic pain, dysmenorrhea, dyspareunia and subfertility (Meuleman et al. 2009; 70 
Giudice & Kao 2004). These symptoms affect general physical, mental and social well-being 71 
and have a significant impact on quality of life (Dunselman et al. 2014). Endometriosis is 72 
currently diagnosed by laparoscopy, but the time to diagnosis can be long (on average 6-7 73 
years) owing to the variability of the symptoms and a lack of diagnostic biomarkers 74 
(Nnoaham et al. 2011). Symptoms can be managed medically or surgically but symptoms 75 
reoccur in up to 75% of surgical cases within 2 years and available medical treatments have 76 
undesirable side effects and are contraceptive (Jacobson et al. 2009). The annual average 77 
health care cost associated with endometriosis in the UK is estimated at £8.5 billion, which is 78 
similar to that of diabetes and rheumatoid arthritis (Simoens et al. 2012).  79 
 80 
Endometriosis is a benign, estrogen-dependent disorder defined as the presence of 81 
endometrial glands and stroma outside the uterine cavity (Giudice 2010). It is now generally 82 
accepted that there are three distinct types of endometriosis: peritoneal, ovarian and deep 83 
endometriosis, each of which is thought to have a different pathogenesis (Nisolle & Donnez 84 
1997). The most common type of endometriosis is peritoneal endometriosis and this is the 85 
focus of our review (Mahmood & Templeton 1991). 86 
 87 
The widely accepted hypothesis for the development of endometriosis is the retrograde 88 
menstruation theory proposed by Sampson in 1927. This theory suggests that during 89 
menstruation viable endometrial tissue is refluxed through the Fallopian tubes into the 90 
peritoneal cavity where it implants and grows (Sampson 1927). Sampson’s theory is 91 
supported by the high prevalence of pelvic endometriosis in girls with congenital menstrual 92 
outflow obstruction and the distribution of lesions in the abdominal cavity (Nap 2004). It is 93 
also supported by the fact that women with endometriosis have more frequent sub-94 
endometrial myometrial contractile waves than women without endometriosis (Salamanca & 95 































































Beltrán 1995)  In addition women with endometriosis have higher volumes of refluxed 96 
menstrual blood than healthy controls (Halme et al. 1984; Salamanca & Beltrán 1995). 97 
However, as retrograde menstruation is seen in over 90% of women, this hypothesis fails to 98 
fully explain why shed endometrial tissue implants in some women and not in others (Halme 99 
et al. 1984).  100 
 101 
It is now agreed that a combination of genetic, hormonal, immunological and anatomical 102 
factors contribute to the formation and development of endometrial lesions (Giudice & Kao 103 
2004). The formation of peritoneal lesions has been attributed to the attachment of ectopic 104 
endometrium to the peritoneal surface, invasion of the peritoneum, neoangiogenesis, 105 
suppression of the immune system and continued survival and growth of lesion tissue 106 
(Giudice & Kao 2004; Young et al, 2013). Increased concentrations of inflammatory 107 
cytokines and growth factors within the peritoneal fluid and peritoneal tissue are thought to 108 
contribute to peritoneal lesion formation (Young et al. 2013). Transforming growth factor 109 
beta (TGF-β) is an inflammatory growth factor that regulates a variety of cellular functions 110 
including cell adhesion, invasion and angiogenesis, all of which are essential during 111 
endometriosis lesion development. Levels of TGF-β are reported to be increased in the 112 
peritoneal fluid, serum, ectopic endometrium and peritoneal tissue of women with 113 
endometriosis compared to controls (Oosterlynck et al. 1994; Pizzo et al. 2002; Chegini et al. 114 
1994; Young et al. 2014a; Young et al. 2014b) and Tgfb1 null mice have reduced 115 
endometriosis lesion growth when compared to wild-type controls (Hull et al. 2012), 116 
suggesting TGF-β1 plays a key role in lesion development. Nevertheless, the functional role 117 
that TGF-β plays in the pathophysiology of endometriosis is less clear. This review will 118 
attempt to highlight the expression pattern and potential roles of TGF-β ligands and signalling 119 
in the pathophysiology of peritoneal endometriosis.   120 
 121 
































































We searched the Pubmed database using the terms ‘transforming growth factor beta’ and 123 
‘endometriosis’ for studies published between 1995 and 2016. The initial search identified 99 124 
studies and these were used as the basic material for this review. We also extended our remit 125 
for important older publications. In addition, we searched the reference lists of studies used in 126 
this review for additional studies we judged as relevant. Studies which were included in the 127 
review focused on peritoneal endometriosis only as increasing evidence suggests that ovarian 128 
and deep endometriosis may have a differing pathophysiology. Thus, a final 95 studies were 129 
included in the review. 130 
RESULTS 131 
The TGF-β signalling pathway 132 
The TGF-β superfamily consists of over 30 different ligands in humans and includes three 133 
TGF-β isoforms, four activin isoforms, 10 bone morphogenetic protein isoforms, 11 growth 134 
and differentiation factor isoforms and the protein nodal (Schmierer & Hill 2007).  TGF-β is 135 
secreted in a latent complex consisting of three proteins: TGF-β, an inhibitor (latency-136 
associated protein, LAP, which is derived from the TGF-β propeptide) and an extracellular 137 
matrix (ECM)-binding protein (latent TGF-β binding proteins, or LTBPs). LTBPs interact 138 
with fibrillins and other ECM components and thus function to localize latent TGF-β in the 139 
ECM. LAP contains an integrin-binding site (RGD), and several RGD-binding integrins are 140 
able to activate latent TGF-β through binding this site (Munger and Sheppard 2011). A 141 
common pathway for TGF-β activation is through integrins; αV-β6 on the surface of 142 
epithelial and mesothelial cells induces a conformational change by binding to the RGD motif 143 
present in LAP and activate TGF-β, inducing adhesion-mediated cell forces that are translated 144 
into biochemical signals which can lead to liberation/activation of TGF-β from its latent 145 
complex (Munger et. Al. 1999, Munger and Sheppard 2011). Secondly, αV-β6 integrin on the 146 































































surface of epithelial and mesothelial cells can activate latent TGF-β by creating a close 147 
connection between the latent TGF-β complex and  matrix metalloproteinase (MMP)-2 and 148 
MMP-9, which can activate TGF-β through proteolytic degradation of the LAP (Yu & 149 
Stamenkovic 2000; Mu et al. 2002; Annes 2003; Wipff and Hinz 2008). Notably integrin αV 150 
and β6 null mice both display similar phenotypes to the Tgfb1 null mice (Bader et al. 1998; 151 
Huang et al. 1996; Shull et al. 1992). In addition to MMPs, other proteases, including 152 
plasmin, have been shown to activate TGF-β ligands through proteolytic degradation (Yu & 153 
Stamenkovic 2000; Annes 2003), together with other factors including an acidic pH, which 154 
denatures the LAP (Lyons et al. 1988), and thrombospondin-1, which induces a 155 
conformational change in LAP thus leading to activation of TGF-β ligands (Schultz-Cherry & 156 
Murphy-Ullrich 1993), Additional pathways may also lead to the activation of TGF-β ligands, 157 
and the diverse range of TGF-β activation pathways demonstrates that this is a key step in the 158 
regulation of TGF-β signalling. Ann s has published a comprehensive review on TGF-β 159 
activation and regulation, which describes these processes and their importance in more depth 160 
(Annes 2003).   161 
 162 
Classically, activated TGF-β ligands bind to the constitutively active transmembrane receptor, 163 
TGF-β receptor II (TGF-βRII), which induces a conformational change and initiates the 164 
recruitment of transmembrane TGF-β receptor I (TGF-βRI) (Figure 1) (Shi & Massague 165 
2003). The TGF-β receptor complex then in turn phosphorylates the receptor regulated 166 
transcription factors SMAD2 and SMAD3 (Figure 1) (Shi & Massague 2003). A third TGF-β 167 
receptor, TGF-β receptor III (TGF-βRIII), has been described and was originally thought to 168 
be a TGF-β co-receptor, presenting TGF-β ligands to TGF-βRII (Cheifetz et al. 1988). More 169 
recently, it has been shown that Tgfb-RIII null mice die at gestational day 13.5 indicating 170 
TGF-βRIII to be an essential component of the TGF-β signalling pathway in development 171 
(Compton et al. 2007). However, little is known about the role of this receptor in TGF-β 172 
signalling.  173 
































































Phosphorylated receptor Smads form a heteromeric complex of two receptor Smads together 175 
with the co-Smad, Smad4, before nuclear translocation and regulation of transcriptional 176 
responses (Figure 1) (Schmierer & Hill 2007). Smad-mediated transcription can be either 177 
positive or negative and is thought to occur through chromatin remodelling and histone 178 
modification rather than direct recruitment of transcriptional machinery (Ross et al. 2006; Shi 179 
& Massague 2003). Inhibitory Smad7 mediates negative feedback in the TGF-β signalling 180 
pathway by competing for TGF-β receptor I binding and inhibiting phosphorylation of Smad2 181 
or Smad3 (Schmierer & Hill 2007). TGF-β signalling through Smad independent pathways, 182 
such as tyrosine kinase and G-protein-coupled signalling pathways, has been described, 183 
although the links between the activated TGF-β receptors and the downstream signalling 184 
molecules remain unknown in most cases (Moustakas 2005). Additionally, TGF-β signalling 185 
through the nodal signalling pathway, a crucial embryogenesis pathway, has been described 186 
in tumorogenesis (Quail et al. 2013; Schmierer & Hill 2007; (Moustakas 2005).   187 
TGF-β signalling elicits a wide variety of downstream processes, however this is in direct 188 
contrast with the number of Smad proteins recruited by the TGF-β receptors and it is not fully 189 
understood how TGF-β ligands can produce a variety of distinct responses (Shi & Massague 190 
2003).  Several theories exist that attempt to explain these responses. Firstly; it has been 191 
reported that distinct signal intensities can stimulate differential gene expression, for example, 192 
the nuclear concentration of a transcriptional activator required for expression is determined 193 
by the binding affinity of a target gene promoter (Schmierer & Hill 2007). Secondly, differing 194 
concentrations of TGF-β ligands can activate different responses in gene expression 195 
(Schmierer & Hill 2007). Thirdly, the establishment of reciprocal gradients of repressor gene 196 
expression have been reported for some genes. Schmierer and Hill describe these processes in 197 
more detail (Schmierer and Hill 2007). More recently, a cell-type-specific master 198 
transcription factor which directs different responses to Smad2 or Smad3 in different cell 199 
types has been reported (Mullen et al. 2011). The mechanism that determines phosphorylation 200 































































of Smad2 over Smad3, or vice-versa, by the TGF-β receptor in a particular cell type is not yet 201 
known (Shi & Massague 2003).  202 
 203 
TGF-β expression in women with peritoneal endometriosis 204 
Several studies have reported significantly higher levels of TGF-β1 in serum, peritoneal fluid, 205 
peritoneum and eutopic endometrial tissue of women with endometriosis when compared to 206 
women without endometriosis, suggesting that altered TGF-β expression and/or signalling 207 
may contribute to the pathophysiology of endometriosis ( Oosterlynck et al. 1994; Chegini et 208 
al. 1994;Kupker et al. 1998; Pizzo et al. 2002; Fan et al. 2005; Young et al. 2014a; Young et 209 
al. 2014b).  210 
Peritoneal mesothelial cells are the largest cell population within the peritoneal cavity and are 211 
reported to overexpress TGF-β, and in particular TGF-β1 ligands, into the peritoneal fluid in 212 
response to peritoneal related pathologies, such as fibrosis and peritoneal cancers, suggesting 213 
that they may play a significant role in the elevated levels of TGF-β1 found in women with 214 
endometriosis (Offner et al. 1996). Recently, we have described the peritoneal mesothelial 215 
cells as a source of TGF-β1 in the pathology of endometriosis through a series of 216 
immunohistohemical staining on primary human peritoneal biopsies and through studies in 217 
vitro of primary peritoneal mesothelial cells (Young et al. 2014b). Additional sources of 218 
peritoneal fluid TGF-β in women with endometriosis are thought to be from shed menstrual 219 
tissue, ectopic endometrial cells and macrophages (Omwandho et al. 2010). The peritoneum 220 
from women with endometriosis has been reported to express significantly higher levels of 221 
TGF-β1, TGF-β3 and Smad3 than the peritoneum from control women with benign ovarian 222 
tumours  (Li et al. 2011). However the nature of the cells contributing to this increase (either 223 
immune cells, nerve cells, endothelial cells or mesothelial cells), is not clear (Li et al. 2011). 224 
Furthermore, as the control group of women included in this study presented with benign 225 
ovarian tumours, it is not clear if the observed differences in TGF-β ligand and Smad3 226 































































expression were linked to the presence of endometriosis or the presence of ovarian pathology 227 
(Li et al. 2011). We have recently described a significant increase in TGF-β1 mRNA 228 
expression in the peritoneum adjacent to endometriosis lesions, when compared to 229 
peritoneum from sites distal to lesions in women with endometriosis. We found no change in 230 
mRNA expression of TGF-β signalling components (TGF-β receptors 1, 2 and Smad3) in the 231 
same tissue set, suggesting that the local increase in TGF-β1 may have downstream 232 
consequences on TGF-β signalling targets within the peritoneum (Young et al. 2014b).   233 
 234 
TGF-β1, 2 and 3 are expressed in the human endometrium and their expression is cyclically 235 
regulated, with all 3 isoforms being expressed during menstration and found in shed 236 
endometrial tissue. Immunohistochemical analysis showed that TGF-β1 was localised within 237 
the stromal cells, glandular cells and macrophages of endometrial tissue, and TGF-β2 and 3 238 
have been localised to the stromal cells and glandular cells of the endometrium (Chegini et al. 239 
1994; Johnson et al. 2005).. Additonally, TGF-β1 protein levels are significantly increased in 240 
the nerve fibres of peritoneal endometriosis lesions, when compared to nerve fibres in 241 
peritoneum from women without endometriosis, and a statistically significant relationship 242 
was found between TGF-β1 expression and dysmenorrhea (Tamburro et al. 2003).  243 
 244 
Despite conclusive evidence that TGF-beta isoforms are expressed and play a crucial 245 
signalling role in human endometrium, there is no literature directly showing TGF-beta 246 
expression and localisation to endometriosis lesion tissue. It is also not yet known if the 247 
increased levels of TGF-β1 in the peritoneal fluid of women with endometriosis precedes or 248 
follows the development of endometriosis. However, as retrograde menstruation and the 249 
presence of endometrial cells within the peritoneal cavity can induce inflammation and TGF-250 
β is an inflammatory cytokine, the development of endometriosis and the increase in TGF-β1 251 
are likely to go hand-in-hand ( D'Hooghe et al. 2001a; D'Hooghe et al. 2001b; Li et al. 2011).  252 
 253 































































Only two of the reported studies indicated whether total or bioactive levels of TGF-β1 were 254 
measured, with both reporting only total levels to be measurable in peritoneal fluid, 255 
suggesting TGF-β ligands are activated locally, and therefore it is important to investigate the 256 
local changes induced by the presence of endoemtriosis lesions in the activation of TGF-β  257 
(Oosterlynck et al. 1994; Young et al. 2014a). One study has examined activation of TGF-β 258 
in women with endometriosis, and this was via the plasminogen activation pathway, which 259 
the authors found to be increased at sites of endometriosis lesions, suggesting that there may 260 
be more TGF-β activity in endometriosis lesions and the surrounding peritoneum (Komiyama 261 
et al. 2007). Several other activation pathways are likely to play a role in peritoneal TGF-β 262 
ligand activation and may be altered in women with endometriosis. Peritoneal mesothelial 263 
cells and endometriosis lesions express several integrins, including integrin αV and β6 which 264 
are known activators of TGF-β ligands, as described above (Odor 1954; Bardi & Hope 1964; 265 
van der Linden et al. 1994). These factors may contribute to the activation of TGF-β ligands 266 
within the local peritoneal enviroment and changes in integrin expression in women with 267 
endometriosis may lead to an increase in TGF-β activity. However, despite this pathway 268 
being a credible mechanism for TGF-β ligand activation in women with endometriosis, it has 269 
not yet been investigated in the pathophysiology of endometriosis. 270 
 271 
TGF-β1 levels may be cyclically regulated within the peritoneal fluid of women and levels of 272 
TGF-β1 are significantly increased in the peritoneal fluid of women with endometriosis when 273 
compared to women without disease (Kupker et al. 1998; Pizzo et al. 2002; Oosterlynck et al. 274 
1994; Young et al. 2014a; Young et al. 2014b). Recently, we reported TGF-β2 and TGF-β3 275 
to be present within the peritoneal fluid, however levels of these ligands remained unchanged 276 
between women with and without endometriosis (Young et al. 2014b).  277 
 278 
Interestingly, only two studies have quantified serum levels of TGF-β in women with 279 
endometriosis compared to women without. Pizzo et al. (2002) examined the levels of TGF-β 280 































































using ELISA in serum and peritoneal fluid isolated from 26 women with endometriosis and  281 
described a significant increase in serum-TGF-β concentrations, which increased with the 282 
severity of the disease and in a similar fashion to peritoneal fluid levels of TGF-β. However, 283 
this study made no distinction between TGF-β isoforms measured and it is not clear if this is 284 
TGF-β1 or all TGF-β ligands (Pizzo et al. 2002). Another study from a different group where 285 
authors have investigated the association between endometriosis and TGF-β1 gene 286 
polymorphisms using restriction fragment length polymorphism analysis and serum TGF-β1 287 
levels in Korean women, independentaly confirmed that serum TGF-β1 levels were 288 
significantly higher in Korean women with endometriosis (n=120) than in controls (n= 89) 289 
(Lee et al. 2011). Both studies described a significant increase in TGF-β or TGF-β1 in the 290 
serum of women with endometriosis compared to controls, suggesting TGF-β may be a 291 
potential biomarker for the detection of endometriosis. 292 
 293 
Endometriotic lesions express TGF-β1, 2 and 3, in differing protein concentrations, with 294 
TGF-β1 being the most abundantly expressed TGFβ protein isoform (Chegini et al. 1994). 295 
TGF-β1 was shown to be expressed in all cell types, except endometrial stromal cells, found 296 
within surgically induced endometriosis lesions in a rat (Chegini et al. 1994). One study 297 
demonstrated TGF-β mRNA expression to be increased in endometriosis lesion tissue when 298 
compared to eutopic endometrial tissue, however it is not clear if the endometrial control 299 
tissue is from women with or without endometriosis and the TGF-β isoforms measured are 300 
not reported (Fan et al. 2005). The TGF-β signal transducers Smad3, pSmad3, and Smad4, 301 
and the inhibitory Smad7 proteins were also observed in the endometrial stromal and 302 
epithelial cells (Luo et al., 2003a) and  suggest a role for TGF-βs in the normal function of the 303 
human endometrium. In eutopic endometrium transcriptional activity of Smad3 is suppressed 304 
by the estrogen receptor (ER) in an estradiol-dependent manner, and ER-mediated 305 
transcription increases after activation of TGF-β signaling (Matsuda et al., 2001; Cherlet and 306 
Murphy, 2007). Studies have also shown that eutopic endometrium express Smads and that 307 































































TGF-β1 increases both the expression of Smad3, and the phosphorylation of Smad3 in vitro 308 
in a dose-dependent manner, suggesting endometriotic cells may also be responsive to TGF-309 
β1 signalling (Luo et al. 2003b). TGF-β1 was shown to be aberrantly expressed in the 310 
endometrium of women with endometriosis when compared to women without endometriosis, 311 
an observation the authors suggested may be linked to the increased cell proliferation seen in 312 
the endometrial cells of women with endometriosis (Johnson et al. 2005).  313 
 314 
Recently, Hull et al. described a reduced growth of endometriosis lesions in TGF-β1-null 315 
mice when compared to their wild-type counterparts, demonstrating TGF-β1 to play a key 316 
role in endometriosis lesion development (Hull et al. 2012) and tissue repair and remodelling 317 
(Hull et al. 2008). These studies have been summarised in Table 1. 318 
 319 
A role for TGF-β1 in the pathophysiology of peritoneal endometriosis 320 
Although TGF-β1 expression appears to be increased in women with endometriosiscompared 321 
to women without endometriosis, less is known about the functional role of TGF-β1 in the 322 
development and maintenance of peritoneal endometriosis. TGF-β1 is a multifunctional 323 
cytokine, which is known to regulate a variety of biological processes e.g. cell proliferation, 324 
ECM formation, tissue remodeling, and inflammation (Massague et al. 2000; Jakowlew 325 
2006). Similar biological events occur during endometriotic lesion establishment, and 326 
although there is little understanding of the signaling events that control them, there is 327 
evidence of TGF-β1 involvement. Herein follows a review of the possible functional roles for 328 
TGF-β1 in the pathophysiology of peritoneal endometriosis.  These functions are summarised 329 
in Table 2.  330 
TGF-β regulation of ectopic endometrial cell survival 331 
TGF-β1, together with its downstream signalling targets involved in cell survival, including 332 
mRNA expression levels of BAX and C-MYC, were shown to be altered in the eutopic 333 































































endometrium of women with endometriosis compared to women without disease (Johnson et 334 
al. 2005), suggesting that increased TGF-β1 may lead to increased apoptosis resistance in the 335 
shed endometrial tissue of women with endometriosis. The change in BAX and C-MYC 336 
expression may facilitate survival of ectopic endometrial tissue during transport to the 337 
peritoneal cavity (Johnson et al. 2005). Furthermore, the increasing concentrations of TGF-β1 338 
in the peritoneal fluid of women with endometriosis may further contribute to the expression 339 
of anti-apoptotic factors in shed endometrial tissue (Seoane 2006). Tgfb1 null mice showed 340 
reduced numbers of endometrial epithelial cells, without any observed changes in cell 341 
proliferation, leading to the hypothesis that TGF-β1 may be responsible for inducing anti-342 
apoptosis effects within these cells, supporting this theory (Hull et al.  2012).  343 
Together with increased apoptosis resistance and decreases in immune cell numbers and 344 
activity within the peritoneal fluid and peritoneum, TGF-β may also contribute to ectopic 345 
tissue survival. TGF-β1 overexpression has been linked to a reduction in peritoneal fluid and 346 
peritoneal tissue natural killer (NK) cell and macrophage numbers leading to suppressed 347 
scavenger function in the peritoneum (Hull et al. 2012; Mizumoto 1996; Dou et al. 1997). 348 
This could limit the clearance of retrograde menstrual tissue within the peritoneal cavity and 349 
may lead to a greater chance of ectopic endometrial cell survival. 350 
TGF-β regulation of ectopic endometrial cell attachment onto the peritoneum 351 
Adhesion of human endometrial cells to mouse peritoneum is increased on exposure to TGF-352 
β1 in an in-vitro co-culture attachment assay (Beliard et al. 2003), but the mechanism by 353 
which TGF-β1 treatment increases ectopic cell adhesion is unclear. It may be induced by 354 
altered expression of cell surface adhesion molecules on the peritoneal mesothelial cells, 355 
changes in the morphology of the peritoneal mesothelial cells exposing the underlying 356 
peritoneal tissue or altered expression of cell surface adhesion molecules on the endometrial 357 
cells, or a combination of some or all of the above (Beliard et al. 2003). As discussed 358 
previously, the mechanism of ectopic endometrial cell attachment to the peritoneum and the 359 
site of ectopic endometrial cell attachment, either directly to the peritoneal mesothelium or to 360 































































the underlying connective tissue, is not fully understood (Dunselman et al. 2001). Another 361 
study using a functional co-culture adhesion assay showed conflicting results, with exposure 362 
to 5ng TGF-β1 significantly increasing attachment of EM42 endometrial epithelial cells to 363 
LP9 peritoneal mesothelial cells, but this was not reproducible for the primary endometrial 364 
epithelial cells (Liu et al. 2009). Additionally, exposure to 10ng TGF-β1 significantly reduced 365 
the attachment of primary endometrial epithelial cells to LP9 peritoneal mesothelial cells, but 366 
this was not reproducible for the EM42 cell line (Liu et al. 2009); in this study, the authors 367 
pre-treated the endometrial epithelial cells with TGF-β1. An interesting follow-up study 368 
would be to repeat the attachment assay with pre-treated peritoneal mesothelial cells, as these 369 
cells will also be in direct contact with the peritoneal fluid and hence the increased TGF-β1 370 
concentrations in women with endometriosis. Moreover the peritoneal mesothelium is a key 371 
defensive barrier: therefore it is more likely that changes within the peritoneal mesothelial 372 
cells than changes to the ectopic endometrial cells increase ectopic cell adhesion and 373 
invasion. 374 
TGF-β regulation of ectopic endometrial cell invasion into the peritoneum 375 
Studies have shown that TGF-β1 enhances ectopic endometrial cell invasion into peritoneal 376 
tissue during the development of endometriosis lesions (Liu et al. 2009). Using a three-377 
dimensional cell invasion assay model, Liu et al. demonstrated that TGF-β1 dose-dependently 378 
increases invasion of EM42 endometrial epithelial cells and primary endometrial epithelial 379 
cells though a monolayer of LP9 peritoneal mesothelial cells, and this effect is inhibited by 380 
addition of a TGF-βR1 antagonist (Liu et al. 2009). The endometrial epithelial cells were pre-381 
treated with either TGF-β1 and/or TGF-βR1 antagonist, showing the effects of TGF-β1 on 382 
ectopic endometrial cells. This study demonstrates that TGF-β1 is able to increase 383 
endometrial epithelial cell invasion and results suggest that TGF-β1 maybe inducing 384 
epithelial to mesenchymal transition (EMT) within these cells, which would explain the 385 
increased migratory and invasion capacity (Liu et al. 2009). EMT within the peritoneal 386 































































mesothelial cells has also been discussed in the pathophysiology of endometriosis by 387 
increasing ectopic endometrial cell attachment or invasion into the peritoneum through 388 
disruption of the mesothelial monolayer (Dunselman et al. 2001; Weusten et al. 2000; Demir 389 
et al. 2004).  390 
TGF-β1 is the most well-known inducer of EMT and one group has demonstrated that TGF-391 
β1 may be a cause of EMT within the ectopic endometrial epithelial cells of endometriosis 392 
lesions in baboons and this was linked to increased cellular contractility and lesion-associated 393 
fibrosis (Zhang et al. 2016a) In a follow-up baboon study, TGF-β1 was confirmed to induce 394 
EMT within ectopic endometrial epithelial cells and immunohistochemical analysis has 395 
shown that concentrations of TGF-β1 and pSmad3 were correlated with the extent of fibrosis 396 
(Zhang at al. 2016b). 397 
TGF-β1 regulation of peritoneal immune cell activity 398 
TGF-β1 autocrine and paracrine signalling within peritoneal macrophage populations were 399 
shown to play an essential role in the development of endometriosis lesions (Dou et al. 1997). 400 
In-vitro functional assays showed that TGF-β1 regulates macrophage DNA synthesis and cell 401 
proliferation, macrophage cell-cell interaction and mRNA expression of several macrophage 402 
cell surface adhesion molecules, including: integrins α2, α3, α4, αv, β1, β6 and platelet-403 
endothelial cell adhesion molecule-1 (Dou et al. 1997). Blocking TGF-β expression and 404 
signalling in these cells using TGF-β1 antisense oligomers prevented these effects (Dou et al. 405 
1997). TGF-β expression by peritoneal macrophages may also regulate integrin expression 406 
both within the ectopic endometrial cells and the peritoneal mesothelial cells, contributing to 407 
ectopic endometrial cell attachment to the peritoneum, however this mechanism has not yet 408 
been discussed within endometriosis literature. Interestingly, peritoneal endometriosis lesions 409 
from Tgfb1-null mice contained significantly reduced numbers of macrophages, when 410 
compared to wild-type control mice, suggesting that TGF-β1 is responsible for the 411 
recruitment of peritoneal macrophages into endometriosis lesions (Hull et al. 2012).  TGF-β 412 































































signalling has been shown to promote M2-type macrophages activation, which are involved 413 
in inflammation, tissue repair and promote removal of apoptotic cells (Depeng Gong 2012). 414 
Recently it was shown that M1-type macrophages suppress endometriotic lesion 415 
development, whereas M2-type macrophages, associated with wound healing and tissue 416 
remodeling, enhance lesion development (Bacci et al. 2009). 417 
 418 
Decreased NK cell activity within the peritoneal cavity in women with endometriosis has 419 
been attributed to increasing concentrations of TGF-β within the peritoneal fluid (Mizumoto 420 
1996). Furthermore, peritoneal fluid from women with endometriosis, or treatment with TGF-421 
β, inhibited the development of mice embryos and this was attributed to the decrease in NK 422 
cell activity, although again the TGF-β isoforms measured or used in treatments is unknown 423 
(Mizumoto 1996). Nevertheless, these results do suggest that increasing TGF-β levels in the 424 
peritoneal fluid, and potentially the endometrium of women with endometriosis, may have an 425 
adverse effect on fertility.  426 
 427 
TGF-β1 regulation of ectopic endometrial cell proliferation 428 
Traditionally, TGF-β1 has been known to have anti-proliferative effects on epithelial cells but 429 
proliferative effects on stromal cells (Seoane 2006). In a mouse model of endometriosis, Hull 430 
et al. (2012) demonstrated no change in endometrial epithelial or stromal cell proliferation in 431 
Tgf-b1 deficient mice, compared to wild-type mice, using BrdU staining. The mouse model 432 
utilised within this study used endometrial tissue from human subjects and therefore the 433 
endometrial cells themselves were not Tgf-β1 deficient, which may explain why no change in 434 
cell proliferation was observed. Supporting the finding that TGF-β1 does not regulate 435 
endometriotic cell proliferation, an in-vitro assay demonstrated TGF-β1 exposure has no 436 
effect on endometrial epithelial cell proliferation, either in primary endometrial epithelial 437 
cells or in the EM42 endometrial epithelial cell line, across several concentrations (Beliard et 438 
al. 2003). Conversely, in another study TGF-β1 was shown to increase protease activated 439 































































receptor 2 (PAR2) mRNA expression and activation in endometrial stromal cells (Saito et al. 440 
2011), and PAR2 has been shown to induce proliferation of endometrial stromal cells  441 
(Yasushi Hirota 2005). Par2-deficient mice also develop smaller and fewer endometriosis 442 
lesions than wild-type counterparts, suggesting a role for TGF-β1-mediated Par2 expression 443 
in ectopic endometrial cell proliferation (Osuga et al. 2008).  444 
TGF-β1 regulation of neoangiogenesis 445 
Neoangiogenesis is a critical step in the pathophysiology of endometriosis and studies have 446 
demonstrated that blocking angiogenesis can block the establishment or growth of 447 
endometriosis lesions in a murine model of endometriosis (Laschke 2005; Hull et al. 2003). 448 
At a macroscopic level, lesions have been shown to be highly vascularised with new vessels 449 
developing from the surrounding peritoneum in hamsters (Overton et al. 2007). Vascular 450 
endothelial growth factor-A (VEGF-A) is the most potent angiogenic factor, which is 451 
increased in the peritoneal fluid of women with endometriosis compared to women without 452 
the disease (McLaren et al. 1996; Kupker et al. 1998; Young et al. 2015). TGF-β1 is an 453 
established regulator of VEGF expression in several cell types and overexpression of TGF-β 454 
and VEGF has been implicated in neoangiogenesis of several cancers (Kaminska et al. 2005). 455 
We have shown that the protein concentrations of VEGF-A in the peritoneal fluid of women 456 
with and without endometriosis correlate with concentrations of TGF-β1, suggesting a 457 
regulatory role for TGF-β1 in the peritoneal expression of VEGF-A (Young et al. 2015). In 458 
the same study, we demonstrated that TGF-β1 may be responsible for the increase in 459 
secretion of VEGF-A from the peritoneal mesothelium through the Inhibitor of DNA Binding 460 
Protein 1 (ID1) pathway, in a similar mechanism to several epithelial cancers, thus 461 
contributing to the vascularisation of endometriosis lesions (Young et al. 2015). 462 
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TGF-β1 regulation of ectopic endometrial and peritoneal mesothelial cell 464 
metabolism 465 
Ectopic endometrial tissue must survive in a hypoxic environment during peritoneal transport, 466 
attachment and invasion into the peritoneum, much like metastatic cancer cells. During 467 
tumour development and metastasis, glycolysis is initially used for energy production, owing 468 
to the hypoxic conditions. Although tumours will eventually develop a blood supply and 469 
hence a supply of oxygen, tumour cells continue to use glycolysis as their main source of 470 
energy production and this phenotype is often referred to as the ‘Warburg effect’ (Gatenby & 471 
Gillies 2004). Side effects of glycolysis include an increase in cell proliferation and motility, 472 
breakdown of ECM and a resistance to apoptosis all of which contribute towards the 473 
progression of the disease (Gatenby & Gillies 2004). The Warburg effect is induced by 474 
inflammatory cytokines, including TGF-β1, via the induction of hypoxia inducible factor 475 
(HIF)-1α protein expression under normoxic conditions (Fosslien 2008; Guido et al. 2012).  476 
There are observations in the literature that suggest ectopic endometrial tissue is using 477 
glycolysis as a means of energy production, such as absence of glycogen deposits, the 478 
presence of small mitochondria and resistance to apoptosis (Jones et al. 2009). Furthermore, 479 
studies have shown HIF-1α to be expressed in endometriosis lesions and HIF-1α  mRNA and 480 
protein expression levels are significantly increased in lesions when compared to matched 481 
eutopic endometrium and healthy control endometrium (Ren et al. 2007; Wu et al. 2007), 482 
although these studies did not link the reported findings to changes in endometriotic cell 483 
metabolism.  484 
We described for the first time potential changes in the cellular metabolism of ectopic 485 
endometrial tissue and the surrounding peritoneal tissue of endometriosis lesions, similar to 486 
that of the Warburg effect seen in tumourigenesis (Young et al. 2014a). In this study we 487 
described significantly higher levels of lactate within the peritoneal fluid of women with 488 
endometriosis and we reported a significant positive correlation between concentrations of 489 
lactate and TGF-β1. These findings were backed up with work in vitro demonstrating that 490 































































TGF-β1 increases lactate concentrations in primary peritoneal mesothelial cells and a 491 
mesothelial cell line, suggesting that TGF-β1 may regulate changes in cell metabolism that 492 
may fuel ectopic endometrial cell survival and endometriosis lesion development (Young et al. 493 
2014a). In a follow up study we demonstrated that TGF-β1 induces changes in the metabolic 494 
phenotype through the inhibitor of DNA-binding protein 2 (ID2) pathway (Young et al. 495 
2016). 496 
 497 
The clinical significance for TGF-β1 in peritoneal endometriosis 498 
Therapeutic moderators of TGF-β expression in endometriosis 499 
GnRH analogues (GnRHa) are commonly used in the medical management of endometriosis 500 
(Panay 2008). While the primary effect is in blocking the production of sex steroids from the 501 
ovary, endometrial stromal cells express GnRH receptors and GnRHa can act directly on 502 
these cells, inducing changes in gene expression, including the expression of TGF-β isoforms 503 
and their receptors (Chegini et al. 2003). Therefore, treatment with GnRHa may have 504 
additional efficacy in the treatment of endometriosis by decreasing the expression and 505 
signalling of TGF-β. TGF-β concentrations in the peritoneal fluid from women with 506 
endometriosis was significantly reduced after 4 months of treatment with a GnRHa, although 507 
the TGFB isoforms measured were not reported (Kupker et al. 1998). It is not clear how much 508 
of this effect is directly mediated by GnRH or indirectly through estrogen removal. 509 
Functional studies have looked at the effects of GnRHa and TGF-β1 exposure on the 510 
expression of fibronectin by endometrial epithelial cells and stromal cells in vitro. Microarray 511 
results demonstrated that TGFB1 significantly increased fibronectin expression, while GnRHa 512 
significantly decreased fibronectin gene expression (Chegini et al. 2003). The authors 513 
concluded that as fibronectin is an essential component in the attachment of ectopic 514 
endometrium to the peritoneum, this might be a mechanism by which GnRHa therapies 515 
influence the development of endometriosis lesions (Chegini et al. 2003). In a follow-up 516 































































study, Luo et al. demonstrated that GnRHa could inhibit phosphorylation of Smad3 in 517 
endometrial stromal cells, suggesting that GnRHa therapies may block TGF-β signalling in 518 
endometrial cells and potentially other cells expressing the GnRH receptors, however whether 519 
this is a direct effect of blocking Smad3 phosphorylation by the TGF-βRI or indirect by 520 
inhibition of TGF-β ligand and receptor expression is unclear (Luo et al. 2003a).  521 
TGF-β polymorphisms in women with endometriosis 522 
Although the exact aetiology of endometriosis remains unclear, genetic predisposition is 523 
thought to play a role. Twin studies have pointed to a genetic component (Montgomery et al. 524 
2008) and women who have a first-degree relative with endometriosis have an increased 525 
chance of developing endometriosis themselves (Giudice & Kao 2004). Several studies have 526 
investigated polymorphisms in the TGFB1 in women with endometriosis, to try and explain 527 
the genetic component of this complex disease. The TGFB1-509C/T polymorphism is the 528 
most commonly researched polymorphism of the TGFB1 gene in the context of 529 
endometriosis, as this polymorphism is the main determinant of plasma TGF-β1 530 
concentrations (Grainger et al. 1999). The results of these studies are inconsistent, with 531 
several studies demonstrating TGFB1 polymorphisms to be associated with endometriosis, 532 
where other studies found no association (Lee et al. 2011; Kim et al. 2010; Hsieh et al. 2005). 533 
A recent meta-analysis of the association of the TGFB1-509C/T polymorphism and the 534 
occurrence of endometriosis found no significant relationship (Zhang et al. 2012). Other 535 
polymorphisms, such as the TGFB1-868T/C, which has been associated with early-stage 536 
endometriosis in Korean women (Lee et al. 2011), may be of future interest in endometriosis 537 
research with regards to its functional impact on endometriosis lesion development and as a 538 
candidate gene marker for endometriosis susceptibility.  539 
 540 
Several genome-wide association studies have now been performed to further investigate the 541 
genetic predisposition associated with endometriosis. A meta-analysis of these studies has 542 
identified eight gene loci to be of possible significance in the pathophysiology of 543 































































endometriosis (Rahmioglu et al. 2014). However, none of these gene loci belonged to the 544 
TGF-β superfamily, indicating that there is unlikely to be a direct genetic linkage resulting 545 
from the TGF-β superfamily (Rahmioglu et al. 2014).  546 
 547 
SUMMARY  548 
 549 
TGF-β regulates a variety of cellular functions including cell proliferation, cell adhesion, cell 550 
migration, cell differentiation, apoptosis, angiogenesis and immune cell function. TGF-β is 551 
overexpressed in the peritoneal fluid of women with endometriosis compared to women 552 
without disease and expression may also be increased in serum, peritoneum, and eutopic 553 
endometrium. Although the expression pattern of TGF-β is documented in the endometriosis 554 
literature, less is reported regarding the functional role(s) that TGF-β plays in the 555 
development and maintenance of endometriosis lesions. However, new mechanistic studies 556 
have recently implicated overexpression of TGF-β in several stages of endometriosis lesion 557 
development.  558 
 559 
Studies have shown that increased levels of TGF-β1 may be responsible for the impaired 560 
immune surveillance within the peritoneum of women with endometriosis owing to its ability 561 
to decrease NK cell activity. This decrease in immune surveillance may facilitate ectopic 562 
endometrial cell survival within the peritoneal cavity. Furthermore, aberrant TGF-β1 563 
expression within eutopic endometrium and peritoneal fluid of women with endometriosis 564 
may increase apoptosis resistance in endometrial cells, further fuelling ectopic endometrial 565 
cell survival. Attachment of ectopic endometrial cells to the surface of peritoneum and 566 
invasion of ectopic cells through the peritoneal mesothelium may increase on exposure to 567 
TGF-β1, although the mechanisms governing this and the cell types altered by TGF-β 568 
signalling, either peritoneal mesothelial cell or ectopic endometrial cell or both, are not 569 
entirely clear. TGF-β1 overexpression may also contribute to ectopic cell survival, invasion 570 































































and angiogenesis though changes in cell metabolism to mimic that of cancer cell metabolism, 571 
and finally TGF-β1 may also regulate neoangiogenesis though expression of VEGF-A.  572 
 573 
Mouse studies using the TGF-β1-null phenotype have given particular insights into the 574 
processes that TGF-β1 is likely to regulate during endometriosis lesion formation. Reduced 575 
numbers of macrophages and myofibroblasts in endometriosis lesions from Tgfb1null mice 576 
suggest TGF-β1 regulation of immune and inflammatory responses. However, there were no 577 
observed changes in cell proliferation or blood vessel density, suggesting that TGF-β1 may 578 
not be essential for cell growth or angiogenesis within peritoneal endometrioses lesions, 579 
contradicting the above observations. However, the overall reduced size and number of 580 
endometriosis lesions in Tgfb1-null mice compared to wild type mice does indicate that 581 
targeting the TGF-β pathway may be of potential therapeutic interest.  582 
 583 
The overexpression of TGF-β1 in the endometriosis microenvironment may contribute to the 584 
pathophysiology in a similar fashion to its oncogenic effects during tumourigenesis, by 585 
inducing changes in cellular metabolism, increasing cell invasion and initiating 586 
neoangiogenesis. Indeed, the same processes that induce TGF-β’s tumour promoting activity 587 
may also be critical in endometriosis lesion development and a switch in TGF-β signalling, 588 
from tumour suppressor to tumour promoter, may help explain hy some women develop 589 
endometriosis and others do not. Endometriosis is associated with an increased risk of several 590 
cancers, including ovarian cancer, breast cancer and non-Hodgkin’s lymphoma, therefore it is 591 
likely that the same causalities or environmental factors which predispose to the development 592 
of endometriosis lesions contribute to the onset of these cancers and vice versa (Kokcu 2011). 593 
This review highlights a key role for TGF-β1 in the pathophysiology of peritoneal 594 
endometriosis and suggests that therapeutic agents which target TGF-β1 expression or its 595 
downstream signalling targets may be beneficial in the prevention and/or treatment of 596 
peritoneal endometriosis.  597 
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Figure legends 852 
 853 
Figure 1. The TGF-β-Smad signalling pathway.  854 
Transforming growth factor β (TGF-β) ligands bind to the receptor TGF-βRII, resulting in a 855 
conformational change that results in the recruitment of TGF-βRI. The TGF-β receptor 856 
complex phosphorylates intracellular receptor regulated Smad2 and Smad3, which form a 857 
dimer before coupling with Smad4 and trans-locating to the nucleus where these transcription 858 
factors regulate gene expression. TGF-β ligands may also bind the TGF-βRIII, which can 859 
present these ligands to the TGF-βRII. TGF-β signalling through the Smad pathway is known 860 
to have impacts on cell growth, angiogenesis, cell differentiation, apoptosis, invasion, 861 
immune cell recruitment and metabolism. Figure is adapted from Schmierer and Hill (2007).   862 
 863 
Figure 2. Schematic representation of the potential roles of TGF-β in the recognised 864 
steps leading to the establishment and progression of peritoneal endometriosis.  865 
HIF-1α = hypoxia inducible factor α, BAX = BCL2-associated X protein, EMT = epithelial to 866 
mesenchymal transition, ID1 = inhibitor of DNA binding 1,  ID2 = inhibitor of DNA binding 867 
2, VEGF = vascular endothelial growth factor, NK=natural killer.868 

































































































































Figure 1 TGF-β-Smad signalling pathway. TGF-β ligands bind to TGF-βRII, resulting in a conformational 
change that results in the recruitment of TGF-βRI. The TGF-β receptor complex phosphorylates intracellular 
receptor regulated Smad2 and Smad3, which form a dimer before coupling with Smad4 and trans-locating to 
the nucleus where these transcription factors regulate gene expression. TGF-β ligands may also bind the 
TGF-βRIII, which can present these ligands to the TGF-βRII. TGF-β signalling through the Smad pathway is 
known to have impacts on cell growth, angiogenesis, cell differentiation, apoptosis, invasion, immune cell 
recruitment and metabolism. Figure is adapted from Schmierer and Hill 2007.    
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Schematic representation of the potential roles of transforming growth factor β  in the recognised steps 
leading to the establishment and progression of peritoneal endometriosis. TGF-β = transforming growth 
factor β; HIF-1α = hypoxia inducible factor α, BAX = BCL2-associated X protein, EMT = epithelial to 
mesenchymal transition, ID1 = inhibitor of DNA binding 1,  ID2 = inhibitor of DNA binding 2, VEGF = 
vascular endothelial growth factor.  
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TGF-β1 Protein Peritoneal fluid  Pelvic pain Significantly 
increased p<0.05 
Young et al., 
2014a 
TGF-β Protein Peritoneal fluid  No pathology Significantly 
increased 
p<0.005 
Kupker et al., 
1998 
TGF-β Protein Peritoneal fluid  Infertility Significantly 
increased 
p<0.001 
Pizzo et al., 
2002 
TGF-β1 Protein Peritoneal fluid  No pathology Significantly 
increased p<0.05 
Oosterlynck 
et al., 1994 
TGF-β1  Protein Peritoneal fluid  Pelvic pain Significantly 
increased p<0.05 
Young et al., 
2014b 
TGF-β2 Protein Peritoneal fluid  Pelvic pain No significant 
change 
Young et al., 
2014b 
TGF-β3 Protein Peritoneal fluid  Pelvic pain No significant 
change 
Young et al., 
2014b 
TGF-β1 mRNA Peritoneum  Pelvic pain Significantly 
increased p<0.05 
Young et al., 
2014b 
TGF-β2 mRNA Peritoneum  Pelvic pain No significant 
change 
Young et al., 
2014b 
TGF-β3 mRNA Peritoneum  Pelvic pain No significant 
change 
Young et al., 
2014b 
TGF-β Protein Serum  Infertility Significantly 
increased 
p<0.001 
Pizzo et al., 
2002 
TGF-β1 Protein Serum Infertility Significantly 
increased 
p<0.0001 
Lee et al., 
2011 
 
Table1. Studies that have measured transforming growth factor (TGF)-β ligand 








































































Function of increased TGF-β1 in 




Increased macrophage proliferation Human Dou et al., 
1997 
Increased macrophage recruitment Mouse Hull et al., 
2012 
Decreased natural killer cell activity Human Mizumoto et 
al., 1996 
Cell survival Increase in anti-apoptopic factors in 
eutopic endometrial tissue  
Human Johnson et al., 
2005 
Increase in anti-apoptopic factors in 
ectopic endometrial tissue 
Human, 
mouse 
Seoane et al., 
2006 
Changes to ectopic endometrial cell 
metabolism linked to apoptosis 
resistance 
Human Young et al., 
2014a 
Cell attachment Increased attachment of endometrial 
cells to mouse peritoneal tissue 
Human Beliard et al., 
2003 
Increased attachment of endometrial 
epithelial cells to peritoneal cells 
Human  Liu et al., 
2009 
Cell invasion Increased invasion of endometrial 
epithelial cells through peritoneal 
mesothelial cells 
Human Liu et al., 
2009 
Disruption of the peritoneal mesothelial 
cell monolayer, allowing for ectopic 
cell invasion 
Human Dunselman et 
al., 2001; 
Demir et al., 
2004 
Changes to ectopic endometrial cell 
metabolism linked to increased cell 
invasion 
Human Young et al., 
2014a 
Angiogenesis Increased expression of angiogeneic 
factors from the peritoneal mesothelium 
Human Young et al., 
2015.  
 
Table 2. Functions that an increase in TGF-β1 has been associated with in the development 
of peritoneal endometriosis lesions.  
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